Scientific Component IV: Pharmacotherapy to Prevent Methamphetamine Relapse

Aaron J. Janowsky1 site in 1 countryJuly 1, 2007

ConditionsAnxiety Relapse Substance Addiction

InterventionsCoreg

DrugsCoreg

Overview

Phase: Phase 2
Intervention: Coreg
Conditions: Anxiety
Sponsor: Aaron J. Janowsky
Locations: 1
Status: Withdrawn
Last Updated: 7 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this research study is to determine whether Carvedilol, an FDA approved beta blocker, when administered for an 8-week period to veterans currently undergoing treatment for methamphetamine dependence (1) improves their ability to stay in treatment longer, (2)eases the aversive symptoms that accompany stimulant withdrawal, and (3) increases the time they remain abstinent from methamphetamine.

Registry

clinicaltrials.gov

Start Date

July 1, 2007

End Date

June 30, 2011

Last Updated

7 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Aaron J. Janowsky

Responsible Party

Sponsor Investigator

Principal Investigator

Aaron J. Janowsky

Director, Methamphetamine Abuse Research Center

Oregon Health and Science University

Eligibility Criteria

Inclusion Criteria

•Must have entered treatment into the outpatient Clinical Addiction Rehabilitation Section (CARS) through the US Portland Veterans Affairs Medical Center
•Must meet the clinical definition for methamphetamine dependence
•Self-reported methamphetamine use within 10 days of entering the study
•Must be able to understand and sign the consent form

Exclusion Criteria

•Dependent on any other drug except nicotine, caffeine, marijuana and alcohol
•Pregnant or nursing mothers
•Psychosis
•Any serious medical condition that could be aggravated by the study protocol (Allergic reaction, Hypotension, Asthma, Bronchospastic conditions, Angina, Bronchitis, Emphysema, Bradycardia, Heart or blood vessel disease, Diabetes mellitus, Low blood sugar, Kidney disease, Liver disease or Overactive thyroid)
•History of withdrawal seizures or delirium tremors
•Use of MAO inhibitors within the last two weeks
•Considerable hepatocellular injury, including cirrhosis of the liver or liver function test levels higher than 2 times normal